Open AccessEffects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis
Author(s) -
Christopher Geven,
Esther Peters,
Mathias Schroedter,
Joachim Struck,
Andreas Bergmann,
Oscar McCook,
Peter Radermacher,
Matthijs Kox,
Peter Pickkers
Publication year - 2018
Publication title -
shock
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.095
H-Index - 117
eISSN - 1540-0514
pISSN - 1073-2322
DOI - 10.1097/shk.0000000000001102
Subject(s) - sepsis , medicine , pharmacology , adrenomedullin , albumin , dose , kidney , renal function , inflammation , immunology , receptor
Adrenomedullin (ADM) is an important regulator of endothelial barrier function during sepsis. Administration of a murine antibody targeted against the N-terminus of ADM (HAM1101) resulted in improved outcome in models of murine sepsis. We studied the effects of a humanized form of this antibody (HAM8101, also known as Adrecizumab) on vascular barrier dysfunction and survival in rodent models of systemic inflammation and sepsis.